Methotrexate therapy in polymyositis

F. C. Arnett, J. C. Whelton, T. M. Zizic, M. B. Stevens

Research output: Contribution to journalArticlepeer-review

Abstract

5 of 16 patients with polymyositis, whose disease could not be controlled with corticosteroids alone, received Methotrexate therapy. 4 had pure polymyositis while one had myositis associated with systemic sclerosis. As a group, they demonstrated, clinically and chemically, more severe muscle disease than those requiring steroids alone. 3 patients clearly responded to the drug, but toxicity was a significant limiting factor. The most serious complication, namely Methotrexate pneumonitis, observed in two patients receiving oral dosage, contributed to death in one. Methotrexate therapy, while a useful adjunct in the steroid refractory patient, is highly toxic, especially when given orally, and must be used with caution.

Original languageEnglish (US)
Pages (from-to)536-546
Number of pages11
JournalAnnals of the rheumatic diseases
Volume32
Issue number6
DOIs
StatePublished - 1973

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Methotrexate therapy in polymyositis'. Together they form a unique fingerprint.

Cite this